A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung

Sponsor
Technische Universität Dresden
Study ID
NCT07561645
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Large Cell Neuroendocrine Carcinoma of the Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Obrixtamig — DRUG
    Obrixtamig (IMP) will be added to Platinum/Etoposide (Standard-of-Care). Three cycles of combined immunochemotherapy 3qw will be followed by maintenance with obrixtamig monotherapy until progression.

Study Details

This phase II clinical trial evaluates the efficacy, safety and tolerability of Obrixtamig in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC.

Key Dates

Start date
Jul 31, 2026
Status verified
Apr 2026
Primary completion
Apr 30, 2032
Completion
Apr 30, 2032

Study Design

Enrollment
75 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Obrixtamig/Platinum/Etoposide
    Obrixtamig/Platinum/Etoposide. Platinum will be carboplatin.

Primary Outcome Measure

Overall Survival (OS) [ Time Frame: app. 69 months ]

Central Contacts

Related Studies